A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections
Levamisole was tested double-blind in 106 children with recurrent upper respiratory tract infections. They received either levamisole (n = 53) or placebo (n = 53) 0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months. A control examination was performed every two months. Both...
Gespeichert in:
| Veröffentlicht in: | European journal of pediatrics 1979-09, Vol.131 (3), p.147-153 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 153 |
|---|---|
| container_issue | 3 |
| container_start_page | 147 |
| container_title | European journal of pediatrics |
| container_volume | 131 |
| creator | Van Eygen, M Dils, F Gillerot, J Verschueren, E |
| description | Levamisole was tested double-blind in 106 children with recurrent upper respiratory tract infections. They received either levamisole (n = 53) or placebo (n = 53) 0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months. A control examination was performed every two months. Both groups were compared by means of the Fisher-test and the Mann-Whitney U-test (two-tailed probability each). Improvement was observed more frequently in the levamisole group with regard to the number of episodes of infection, and the total duration and severity of the infections. No side-effects, except for some stomach complaints in one levamisole patient, were reported. |
| doi_str_mv | 10.1007/BF00538939 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74725004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74725004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-c34122b3217bac0fdb591f0214abfbfe06974e0e0bb039e5ee4a1d72280d9c943</originalsourceid><addsrcrecordid>eNpFkD1PwzAQhi3EVykszAyeGJAC54_E9VgqCkiVWGCObOcsgtwk2Eml_ntStcB0enXPvdI9hFwzuGcA6uFxCZCLmRb6iEyYFDxjoIpjMgEhISuY1ufkIqUvGGHNZmfkVCpVqGJC0pxW7WADZjbUTUU7rGrTx9pR3JgwmL5uG9p6Gsa4rlMbkNYN7T-RdhE32PzuI7ohxjHToeswjjl1dTR9G7e0j8b145lHt8PTJTnxJiS8Oswp-Vg-vS9estXb8-tivsocn7E-c0Iyzq3gTFnjwFc218wDZ9JYbz1CoZVEQLAWhMYcURpWKc5nUGmnpZiS231vF9vvAVNfjh84DME02A6pVFLxHGAH3u1BF9uUIvqyi_XaxG3JoNwJLv8Fj_DNoXWwa6z-0L1R8QP5Nnfr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74725004</pqid></control><display><type>article</type><title>A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Van Eygen, M ; Dils, F ; Gillerot, J ; Verschueren, E</creator><creatorcontrib>Van Eygen, M ; Dils, F ; Gillerot, J ; Verschueren, E</creatorcontrib><description>Levamisole was tested double-blind in 106 children with recurrent upper respiratory tract infections. They received either levamisole (n = 53) or placebo (n = 53) 0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months. A control examination was performed every two months. Both groups were compared by means of the Fisher-test and the Mann-Whitney U-test (two-tailed probability each). Improvement was observed more frequently in the levamisole group with regard to the number of episodes of infection, and the total duration and severity of the infections. No side-effects, except for some stomach complaints in one levamisole patient, were reported.</description><identifier>ISSN: 0340-6199</identifier><identifier>EISSN: 1432-1076</identifier><identifier>DOI: 10.1007/BF00538939</identifier><identifier>PMID: 477676</identifier><language>eng</language><publisher>Germany</publisher><subject>Child ; Double-Blind Method ; Evaluation Studies as Topic ; Female ; Humans ; Levamisole - therapeutic use ; Male ; Recurrence ; Respiratory Tract Infections - prevention & control</subject><ispartof>European journal of pediatrics, 1979-09, Vol.131 (3), p.147-153</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-c34122b3217bac0fdb591f0214abfbfe06974e0e0bb039e5ee4a1d72280d9c943</citedby><cites>FETCH-LOGICAL-c281t-c34122b3217bac0fdb591f0214abfbfe06974e0e0bb039e5ee4a1d72280d9c943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/477676$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Eygen, M</creatorcontrib><creatorcontrib>Dils, F</creatorcontrib><creatorcontrib>Gillerot, J</creatorcontrib><creatorcontrib>Verschueren, E</creatorcontrib><title>A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections</title><title>European journal of pediatrics</title><addtitle>Eur J Pediatr</addtitle><description>Levamisole was tested double-blind in 106 children with recurrent upper respiratory tract infections. They received either levamisole (n = 53) or placebo (n = 53) 0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months. A control examination was performed every two months. Both groups were compared by means of the Fisher-test and the Mann-Whitney U-test (two-tailed probability each). Improvement was observed more frequently in the levamisole group with regard to the number of episodes of infection, and the total duration and severity of the infections. No side-effects, except for some stomach complaints in one levamisole patient, were reported.</description><subject>Child</subject><subject>Double-Blind Method</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Levamisole - therapeutic use</subject><subject>Male</subject><subject>Recurrence</subject><subject>Respiratory Tract Infections - prevention & control</subject><issn>0340-6199</issn><issn>1432-1076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1979</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkD1PwzAQhi3EVykszAyeGJAC54_E9VgqCkiVWGCObOcsgtwk2Eml_ntStcB0enXPvdI9hFwzuGcA6uFxCZCLmRb6iEyYFDxjoIpjMgEhISuY1ufkIqUvGGHNZmfkVCpVqGJC0pxW7WADZjbUTUU7rGrTx9pR3JgwmL5uG9p6Gsa4rlMbkNYN7T-RdhE32PzuI7ohxjHToeswjjl1dTR9G7e0j8b145lHt8PTJTnxJiS8Oswp-Vg-vS9estXb8-tivsocn7E-c0Iyzq3gTFnjwFc218wDZ9JYbz1CoZVEQLAWhMYcURpWKc5nUGmnpZiS231vF9vvAVNfjh84DME02A6pVFLxHGAH3u1BF9uUIvqyi_XaxG3JoNwJLv8Fj_DNoXWwa6z-0L1R8QP5Nnfr</recordid><startdate>197909</startdate><enddate>197909</enddate><creator>Van Eygen, M</creator><creator>Dils, F</creator><creator>Gillerot, J</creator><creator>Verschueren, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197909</creationdate><title>A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections</title><author>Van Eygen, M ; Dils, F ; Gillerot, J ; Verschueren, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-c34122b3217bac0fdb591f0214abfbfe06974e0e0bb039e5ee4a1d72280d9c943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1979</creationdate><topic>Child</topic><topic>Double-Blind Method</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Levamisole - therapeutic use</topic><topic>Male</topic><topic>Recurrence</topic><topic>Respiratory Tract Infections - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Eygen, M</creatorcontrib><creatorcontrib>Dils, F</creatorcontrib><creatorcontrib>Gillerot, J</creatorcontrib><creatorcontrib>Verschueren, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Eygen, M</au><au>Dils, F</au><au>Gillerot, J</au><au>Verschueren, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections</atitle><jtitle>European journal of pediatrics</jtitle><addtitle>Eur J Pediatr</addtitle><date>1979-09</date><risdate>1979</risdate><volume>131</volume><issue>3</issue><spage>147</spage><epage>153</epage><pages>147-153</pages><issn>0340-6199</issn><eissn>1432-1076</eissn><abstract>Levamisole was tested double-blind in 106 children with recurrent upper respiratory tract infections. They received either levamisole (n = 53) or placebo (n = 53) 0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months. A control examination was performed every two months. Both groups were compared by means of the Fisher-test and the Mann-Whitney U-test (two-tailed probability each). Improvement was observed more frequently in the levamisole group with regard to the number of episodes of infection, and the total duration and severity of the infections. No side-effects, except for some stomach complaints in one levamisole patient, were reported.</abstract><cop>Germany</cop><pmid>477676</pmid><doi>10.1007/BF00538939</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6199 |
| ispartof | European journal of pediatrics, 1979-09, Vol.131 (3), p.147-153 |
| issn | 0340-6199 1432-1076 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_74725004 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Child Double-Blind Method Evaluation Studies as Topic Female Humans Levamisole - therapeutic use Male Recurrence Respiratory Tract Infections - prevention & control |
| title | A double-blind pediatric evaluation of levamisole in the prevention of recurrent upper respiratory tract infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A22%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20double-blind%20pediatric%20evaluation%20of%20levamisole%20in%20the%20prevention%20of%20recurrent%20upper%20respiratory%20tract%20infections&rft.jtitle=European%20journal%20of%20pediatrics&rft.au=Van%20Eygen,%20M&rft.date=1979-09&rft.volume=131&rft.issue=3&rft.spage=147&rft.epage=153&rft.pages=147-153&rft.issn=0340-6199&rft.eissn=1432-1076&rft_id=info:doi/10.1007/BF00538939&rft_dat=%3Cproquest_cross%3E74725004%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74725004&rft_id=info:pmid/477676&rfr_iscdi=true |